Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Jul 2022
Historique:
revised: 11 04 2022
received: 18 03 2022
accepted: 27 04 2022
pubmed: 8 5 2022
medline: 15 7 2022
entrez: 7 5 2022
Statut: ppublish

Résumé

Early diagnosis of urological diseases is often difficult due to the lack of specific biomarkers. More powerful and less invasive biomarkers that can be used simultaneously to identify urological diseases could improve patient outcomes. The aim of this study was to evaluate a urological disease-specific scoring system established with a machine learning (ML) approach using Ig N-glycan signatures. Immunoglobulin N-glycan signatures were analyzed by capillary electrophoresis from 1312 serum subjects with hormone-sensitive prostate cancer (n = 234), castration-resistant prostate cancer (n = 94), renal cell carcinoma (n = 100), upper urinary tract urothelial cancer (n = 105), bladder cancer (n = 176), germ cell tumors (n = 73), benign prostatic hyperplasia (n = 95), urosepsis (n = 145), and urinary tract infection (n = 21) as well as healthy volunteers (n = 269). Immunoglobulin N-glycan signature data were used in a supervised-ML model to establish a scoring system that gave the probability of the presence of a urological disease. Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC). The supervised-ML urologic disease-specific scores clearly discriminated the urological diseases (AUC 0.78-1.00) and found a distinct N-glycan pattern that contributed to detect each disease. Limitations included the retrospective and limited pathological information regarding urological diseases. The supervised-ML urological disease-specific scoring system based on Ig N-glycan signatures showed excellent diagnostic ability for nine urological diseases using a one-time serum collection and could be a promising approach for the diagnosis of urological diseases.

Identifiants

pubmed: 35524940
doi: 10.1111/cas.15395
pmc: PMC9277255
doi:

Substances chimiques

Biomarkers, Tumor 0
Immunoglobulins 0
Polysaccharides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2434-2445

Subventions

Organisme : Center of Innovation Program
ID : JPMJCE1302
Organisme : Center of Innovation Program
ID : R03W14
Organisme : Japan Society for the Promotion of Science
ID : 20K18083
Organisme : Japan Society for the Promotion of Science
ID : 20K18130

Informations de copyright

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

Cancer Sci. 2021 Jul;112(7):2905-2914
pubmed: 33931925
Br J Cancer. 2022 Feb;126(3):331-350
pubmed: 34811504
Circ Res. 2018 May 25;122(11):1555-1564
pubmed: 29535164
Hum Immunol. 2016 Nov;77(11):1076-1083
pubmed: 26546874
Biomed Res Int. 2021 Jul 16;2021:9969344
pubmed: 34327242
Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1127-35
pubmed: 26581149
Cancer Sci. 2022 Jul;113(7):2434-2445
pubmed: 35524940
Cancer Med. 2016 Jun;5(6):1137-46
pubmed: 26880719
J Urol. 2014 Mar;191(3):805-13
pubmed: 24140550
Int J Nephrol Renovasc Dis. 2014 Oct 30;7:409-14
pubmed: 25378944
Int J Mol Sci. 2017 Feb 22;18(2):
pubmed: 28241428
Springer Semin Immunopathol. 1988;10(2-3):231-49
pubmed: 3055379
Proteomics. 2009 Feb;9(4):882-913
pubmed: 19212958
Eur Urol Focus. 2018 Apr;4(3):405-411
pubmed: 28753809
J Gastroenterol. 2013 Oct;48(10):1171-9
pubmed: 23307043
Cancer Med. 2017 Apr;6(4):739-748
pubmed: 28317343
Cancer Med. 2021 Feb;10(4):1297-1313
pubmed: 33455069
Int J Mol Sci. 2017 Dec 06;18(12):
pubmed: 29210993
Keio J Med. 2020 Dec 25;69(4):88-96
pubmed: 32404538
PLoS One. 2018 Jul 24;13(7):e0201208
pubmed: 30040854
Elife. 2021 Oct 26;10:
pubmed: 34696827
Medicine (Baltimore). 2021 Jul 9;100(27):e26555
pubmed: 34232197
Prostate. 2021 Dec;81(16):1411-1427
pubmed: 34549452
Front Oncol. 2020 Dec 04;10:543817
pubmed: 33344224
Clin Cancer Res. 2019 May 15;25(10):3016-3025
pubmed: 30808771
BMC Urol. 2017 Apr 4;17(1):25
pubmed: 28376750
Chest. 1992 Jun;101(6):1644-55
pubmed: 1303622
Biomedicines. 2021 Nov 20;9(11):
pubmed: 34829962
J Neuroinflammation. 2015 Dec 18;12:235
pubmed: 26683050
Science. 2006 Aug 4;313(5787):670-3
pubmed: 16888140
ACS Sens. 2020 Jun 26;5(6):1689-1698
pubmed: 32466640
Sci Rep. 2019 Nov 14;9(1):16761
pubmed: 31727974
Cancer Sci. 2019 Jan;110(1):408-419
pubmed: 30382619
J Autoimmun. 2015 Feb;57:1-13
pubmed: 25578468

Auteurs

Hiromichi Iwamura (H)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Kei Mizuno (K)

Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Shusuke Akamatsu (S)

Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Shingo Hatakeyama (S)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Yuki Tobisawa (Y)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Shintaro Narita (S)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Takuma Narita (T)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Shinichi Yamashita (S)

Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Sadafumi Kawamura (S)

Department of Urology, Miyagi Cancer Center, Natori, Japan.

Toshihiko Sakurai (T)

Department of Urology, Yamagata University Graduate School of Medicine, Yamagata, Japan.

Naoki Fujita (N)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Hirotake Kodama (H)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Daisuke Noro (D)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Ikuko Kakizaki (I)

Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Shigeyuki Nakaji (S)

Department of Social Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Ken Itoh (K)

Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Department of Stress Response Science, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Norihiko Tsuchiya (N)

Department of Urology, Yamagata University Graduate School of Medicine, Yamagata, Japan.

Akihiro Ito (A)

Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Tomonori Habuchi (T)

Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

Chikara Ohyama (C)

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Department of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Tohru Yoneyama (T)

Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH